IS2869B - Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini - Google Patents

Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini

Info

Publication number
IS2869B
IS2869B IS6576A IS6576A IS2869B IS 2869 B IS2869 B IS 2869B IS 6576 A IS6576 A IS 6576A IS 6576 A IS6576 A IS 6576A IS 2869 B IS2869 B IS 2869B
Authority
IS
Iceland
Prior art keywords
treatment
breast cancer
filvestrant
persistent
persistent breast
Prior art date
Application number
IS6576A
Other languages
English (en)
Icelandic (is)
Other versions
IS6576A (is
Inventor
Beat Thurlimann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2869(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6576A publication Critical patent/IS6576A/is
Publication of IS2869B publication Critical patent/IS2869B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6576A 2000-04-05 2002-10-01 Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini IS2869B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (2)

Publication Number Publication Date
IS6576A IS6576A (is) 2002-10-01
IS2869B true IS2869B (is) 2014-03-15

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6576A IS2869B (is) 2000-04-05 2002-10-01 Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini

Country Status (28)

Country Link
US (2) US20030158166A1 (enExample)
EP (2) EP1586323A1 (enExample)
JP (1) JP2003528919A (enExample)
KR (1) KR100757764B1 (enExample)
CN (1) CN1431905A (enExample)
AT (1) ATE306270T1 (enExample)
AU (2) AU2001244372B2 (enExample)
BR (1) BR0109789A (enExample)
CA (1) CA2403608A1 (enExample)
CH (1) CH1272195H1 (enExample)
CZ (1) CZ303096B6 (enExample)
DE (1) DE60113975T2 (enExample)
DK (1) DK1272195T3 (enExample)
EE (1) EE05026B1 (enExample)
ES (1) ES2248300T3 (enExample)
GB (1) GB0008172D0 (enExample)
HU (1) HU230064B1 (enExample)
IL (2) IL151932A0 (enExample)
IS (1) IS2869B (enExample)
MX (1) MXPA02009744A (enExample)
NO (1) NO329949B1 (enExample)
NZ (1) NZ539603A (enExample)
PL (1) PL201175B1 (enExample)
RU (1) RU2265438C2 (enExample)
SK (1) SK287779B6 (enExample)
UA (1) UA80388C2 (enExample)
WO (1) WO2001074366A1 (enExample)
ZA (1) ZA200207538B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004102393A (ru) * 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
US8324194B2 (en) * 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
SG194735A1 (en) * 2011-05-09 2013-12-30 Univ Virginia Patent Found Compositions and methods for treating cancer
ES2708302T3 (es) 2011-05-20 2019-04-09 Capital Business Y Gestion De Finanzas S L Composición farmacéutica
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
US20210253626A1 (en) * 2018-05-24 2021-08-19 Kashiv Biosciences, Llc Prodrugs of fulvestrant
KR20220042352A (ko) 2019-07-03 2022-04-05 아토사 테라퓨틱스, 인크. 엔독시펜의 서방성 조성물
EP4110344A4 (en) * 2020-02-29 2024-03-13 The University Of Vermont USE OF THYROMIMETICS TO TREAT CANCER

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
BR0109789A (pt) 2003-01-21
PL201175B1 (pl) 2009-03-31
EP1272195B1 (en) 2005-10-12
NO20024735L (no) 2002-11-27
CA2403608A1 (en) 2001-10-11
US20110183949A1 (en) 2011-07-28
HUP0300339A3 (en) 2009-01-28
ATE306270T1 (de) 2005-10-15
DE60113975D1 (de) 2006-02-23
DK1272195T3 (da) 2006-01-16
GB0008172D0 (en) 2000-05-24
EE05026B1 (et) 2008-06-16
CN1431905A (zh) 2003-07-23
JP2003528919A (ja) 2003-09-30
HU230064B1 (hu) 2015-06-29
CZ303096B6 (cs) 2012-04-04
EP1272195A1 (en) 2003-01-08
IS6576A (is) 2002-10-01
NO20024735D0 (no) 2002-10-02
RU2265438C2 (ru) 2005-12-10
ES2248300T3 (es) 2006-03-16
ZA200207538B (en) 2003-12-19
IL151932A (en) 2007-07-04
WO2001074366A1 (en) 2001-10-11
PL357936A1 (en) 2004-08-09
MXPA02009744A (es) 2004-02-26
US20030158166A1 (en) 2003-08-21
KR20030007501A (ko) 2003-01-23
UA80388C2 (en) 2007-09-25
NZ539603A (en) 2008-02-29
CH1272195H1 (enExample) 2019-10-15
SK14292002A3 (sk) 2003-08-05
AU4437201A (en) 2001-10-15
AU2001244372B2 (en) 2006-02-16
DE60113975T2 (de) 2006-06-22
EE200200574A (et) 2004-04-15
HK1051498A1 (en) 2003-08-08
NO329949B1 (no) 2011-01-31
SK287779B6 (sk) 2011-09-05
IL151932A0 (en) 2003-04-10
KR100757764B1 (ko) 2007-09-12
CZ20023309A3 (cs) 2003-02-12
HUP0300339A2 (hu) 2003-06-28
EP1586323A1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
IS2869B (is) Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
FR08C0013I2 (fr) Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
MY138883A (en) Use of asiatic acid for treatment of cencer
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
PL356784A1 (pl) Substancja do zastosowania w leczeniu łuszczycy
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
DE60222664D1 (de) Hautbehandlungsmittel
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
NO20005548L (no) Mykobakterieinhibitorer
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE297745T1 (de) Chemische modifizierung von harn von säugern
UA28113C2 (uk) Спосіб експрес-тестування ефективності реабілітації здоров'я людини
DK199900219U3 (da) Kiropraktisk behandlings- og sidelejebehandlingsbord
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
FI20000549A0 (fi) Sexi-hoito ja hierontapöytä